FibroGen Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 103 out of 398 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 43.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
Its latest quarterly revenue reached 1.08M, representing a year-over-year decrease of 97.68%, while its net profit experienced a year-over-year decrease of 1274.41%.
Key Metrics
The current valuation score of FibroGen Inc is 8.32, ranking 52 out of 398 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.18, which is 3.41% below the recent high of 0.19 and 15981.12% above the recent low of -28.86.
The current earnings forecast score of FibroGen Inc is 7.00, ranking 316 out of 398 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 43.00 and a low of 43.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of FibroGen Inc is 8.56, ranking 95 out of 398 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.69 and the support level at 8.52, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The latest institutional shareholding proportion is 46.81%, representing a quarter-over-quarter decrease of 1.68%. The largest institutional shareholder is The Vanguard, holding a total of 184.24K shares, representing 4.55% of shares outstanding, with 21.46% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of FibroGen Inc is 2.89, ranking 188 out of 398 in the Biotechnology & Medical Research industry. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
